Emergent BioSolutions (EBS) issued a statement on the status of its response to FDA

May 12, 2021 8:41 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Emergent BioSolutions (NYSE: EBS):

On May 12, 2021, Emergent BioSolutions Inc. (the “Company”) issued a statement on the status of its response to the U.S. Food and Drug Administration’s observations related to the Company’s Baltimore Bayview facility. A copy of the Company statement is attached hereto as Exhibit 99.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

FDA